Haleon plc
Haleon plc scores highest on Price (55) and lowest on Earnings (31). Its PosiPenta is 48.21 out of 100, around the middle of similar companies.
On the Penta Grid this week, Haleon plc is Grid #5 of 8 in the Healthcare sector in United Kingdom, and Grid #67 of 98 in United Kingdom.
Compared with similar companies in the Healthcare sector in United Kingdom.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Haleon plc | 48.21 | 55 | 31 | 50 | 52 | 53 |
| Roivant Sciences Ltd. | 38.43 | 9 | 11 | 68 | 52 | 52 |
| GSK plc | 56.38 | 51 | 63 | 30 | 59 | 79 |
| Smith & Nephew plc | 43.29 | 52 | 55 | 17 | 46 | 46 |
| AstraZeneca PLC | 53.32 | 34 | 79 | 30 | 66 | 58 |
| Convatec Group PLC | 39.93 | 23 | 50 | 64 | 27 | 35 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | 20.94 |
| P/B ratio | 2.02 |
EEarnings
| Trailing EPS | ₹22.74 |
| Forward EPS | ₹28.90 |
NNitro
| Price | 476.36 |
| 52-week high | 547.88 |
| 52-week low | 401.56 |
| Fall from 52-week high | 13.1% |
TTorque
| Return on equity (ROE) | 10.09% |
| Debt-to-equity | 0.50 |
AAnchor
| Beta (price swings) | 0.28 |
| Market cap | ₹4,18,971 Cr |
| Insider holding | 0.07% |
| Dividend yield | 1.95% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Haleon plc's PosiPenta score?
Haleon plc's PosiPenta is 48.21 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Haleon plc stand on the Penta Grid?
On the Penta Grid this week, Haleon plc is Grid #5 of 8 in the Healthcare sector in United Kingdom, and Grid #67 of 98 in United Kingdom.
Which PosiPenta pillar is strongest for Haleon plc?
Price (valuation), with a score of 55 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Haleon plc?
Earnings (growth), with a score of 31 out of 100: weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.